Literature DB >> 27081096

Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm.

Yue Yang1, Hajime Akada1, Dipmoy Nath1, Robert E Hutchison2, Golam Mohi1.   

Abstract

An activating JAK2V617F mutation has been found in ∼50% patients with myelofibrosis (MF). Inactivating mutations in histone methyltransferase enhancer of zeste homolog 2 (EZH2) also have been observed in patients with MF. Interestingly, inactivating EZH2 mutations are often associated with JAK2V617F mutation in MF, although their contributions in the pathogenesis of MF remain elusive. To determine the effects of concomitant loss of EZH2 and JAK2V617F mutation in hematopoiesis, we generated Ezh2-deficient Jak2V617F-expressing mice. Whereas expression of Jak2V617F alone induced a polycythemia vera-like disease, concomitant loss of Ezh2 significantly reduced the red blood cell and hematocrit parameters but increased the platelet counts in Jak2V617F knock-in mice. Flow cytometric analysis showed impairment of erythroid differentiation and expansion of megakaryocytic precursors in Ezh2-deficient Jak2V617F mice. Moreover, loss of Ezh2 enhanced the repopulation capacity of Jak2V617F-expressing hematopoietic stem cells. Histopathologic analysis revealed extensive fibrosis in the bone marrow (BM) and spleen of Ezh2-deleted Jak2V617F mice. Transplantation of BM from Ezh2-deleted Jak2V617F mice into wild-type animals resulted in even faster progression to MF. Gene expression profiling and chromatin immunoprecipitation sequence analysis revealed that S100a8, S100a9, Ifi27l2a, and Hmga2 were transcriptionally derepressed, and the H3K27me3 levels in these gene promoters were significantly reduced on Ezh2 deletion in hematopoietic progenitors of Jak2V617F mice. Furthermore, overexpression of S100a8, S100a9, Ifi27l2a, or Hmga2 significantly increased megakaryocytic colonies in the BM of Jak2V617F mice, indicating a role for these Ezh2 target genes in altered megakaryopoiesis involved in MF. Overall, our results suggest that loss of Ezh2 cooperates with Jak2V617F in the development of MF in Jak2V617F-expressing mice.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27081096      PMCID: PMC4929929          DOI: 10.1182/blood-2015-11-679431

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  55 in total

1.  Ezh1 is required for hematopoietic stem cell maintenance and prevents senescence-like cell cycle arrest.

Authors:  Isabel Hidalgo; Antonio Herrera-Merchan; Jose Manuel Ligos; Laura Carramolino; Javier Nuñez; Fernando Martinez; Orlando Dominguez; Miguel Torres; Susana Gonzalez
Journal:  Cell Stem Cell       Date:  2012-11-02       Impact factor: 24.633

2.  Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.

Authors:  Ayalew Tefferi
Journal:  Am J Hematol       Date:  2014-09       Impact factor: 10.047

3.  Letter: Bone-marrow responses in polycythemia vera.

Authors:  J F Prchal; A A Axelrad
Journal:  N Engl J Med       Date:  1974-06-13       Impact factor: 91.245

4.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.

Authors:  Hajime Akada; Dongqing Yan; Haiying Zou; Steven Fiering; Robert E Hutchison; M Golam Mohi
Journal:  Blood       Date:  2010-03-02       Impact factor: 22.113

Review 7.  S100 proteins in cancer.

Authors:  Anne R Bresnick; David J Weber; Danna B Zimmer
Journal:  Nat Rev Cancer       Date:  2015-02       Impact factor: 60.716

8.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.

Authors:  Wendy Béguelin; Relja Popovic; Matt Teater; Yanwen Jiang; Karen L Bunting; Monica Rosen; Hao Shen; Shao Ning Yang; Ling Wang; Teresa Ezponda; Eva Martinez-Garcia; Haikuo Zhang; Yupeng Zheng; Sharad K Verma; Michael T McCabe; Heidi M Ott; Glenn S Van Aller; Ryan G Kruger; Yan Liu; Charles F McHugh; David W Scott; Young Rock Chung; Neil Kelleher; Rita Shaknovich; Caretha L Creasy; Randy D Gascoyne; Kwok-Kin Wong; Leandro Cerchietti; Ross L Levine; Omar Abdel-Wahab; Jonathan D Licht; Olivier Elemento; Ari M Melnick
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

9.  Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice.

Authors:  Shu Xing; Tina Ho Wanting; Wanming Zhao; Junfeng Ma; Shaofeng Wang; Xuesong Xu; Qingshan Li; Xueqi Fu; Mingjiang Xu; Zhizhuang Joe Zhao
Journal:  Blood       Date:  2008-03-11       Impact factor: 22.113

10.  Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl.

Authors:  W S Alexander; A W Roberts; N A Nicola; R Li; D Metcalf
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

View more
  36 in total

Review 1.  GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy.

Authors:  Te Ling; John D Crispino; Maria Zingariello; Fabrizio Martelli; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2018-02-19       Impact factor: 2.929

Review 2.  Myeloproliferative neoplasm stem cells.

Authors:  Adam J Mead; Ann Mullally
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

3.  The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype.

Authors:  Ashley A Basiorka; Kathy L McGraw; Erika A Eksioglu; Xianghong Chen; Joseph Johnson; Ling Zhang; Qing Zhang; Brittany A Irvine; Thomas Cluzeau; David A Sallman; Eric Padron; Rami Komrokji; Lubomir Sokol; Rebecca C Coll; Avril A B Robertson; Matthew A Cooper; John L Cleveland; Luke A O'Neill; Sheng Wei; Alan F List
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

4.  Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms.

Authors:  Koki Ueda; Kazuhiko Ikeda; Takayuki Ikezoe; Kayo Harada-Shirado; Kazuei Ogawa; Yuko Hashimoto; Takahiro Sano; Hiroshi Ohkawara; Satoshi Kimura; Akiko Shichishima-Nakamura; Yuichi Nakamura; Yayoi Shikama; Tsutomu Mori; Philip J Mason; Monica Bessler; Soji Morishita; Norio Komatsu; Kotaro Shide; Kazuya Shimoda; Shuhei Koide; Kazumasa Aoyama; Motohiko Oshima; Atsushi Iwama; Yasuchika Takeishi
Journal:  Blood Adv       Date:  2017-06-14

5.  Systems-Based Interactome Analysis for Hematopoiesis Effect of Angelicae sinensis Radix: Regulated Network of Cell Proliferation towards Hemopoiesis.

Authors:  Guang Zheng; He Zhang; Yun Yang; Ying-Li Sun; Yan-Jing Zhang; Ju-Ping Chen; Ting Hao; Cheng Lu; Hong-Tao Guo; Ge Zhang; Dan-Ping Fan; Xiao-Juan He; Ai-Ping Lu
Journal:  Chin J Integr Med       Date:  2018-06-25       Impact factor: 1.978

6.  TLR4 and RAGE conversely mediate pro-inflammatory S100A8/9-mediated inhibition of proliferation-linked signaling in myeloproliferative neoplasms.

Authors:  Marijana Kovačić; Olivera Mitrović-Ajtić; Bojana Beleslin-Čokić; Dragoslava Djikić; Tijana Subotički; Miloš Diklić; Danijela Leković; Mirjana Gotić; Pascal Mossuz; Vladan P Čokić
Journal:  Cell Oncol (Dordr)       Date:  2018-06-26       Impact factor: 6.730

7.  Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation.

Authors:  Zhimin Gu; Yuxuan Liu; Feng Cai; McKenzie Patrick; Jakub Zmajkovic; Hui Cao; Yuannyu Zhang; Alpaslan Tasdogan; Mingyi Chen; Le Qi; Xin Liu; Kailong Li; Junhua Lyu; Kathryn E Dickerson; Weina Chen; Min Ni; Matthew E Merritt; Sean J Morrison; Radek C Skoda; Ralph J DeBerardinis; Jian Xu
Journal:  Cancer Discov       Date:  2019-06-12       Impact factor: 39.397

8.  JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells.

Authors:  Hamza Celik; Won Kyun Koh; Ashley C Kramer; Elizabeth L Ostrander; Cates Mallaney; Daniel A C Fisher; Jingyu Xiang; William C Wilson; Andrew Martens; Alok Kothari; Gregory Fishberger; Eric Tycksen; Darja Karpova; Eric J Duncavage; Youngsook Lee; Stephen T Oh; Grant A Challen
Journal:  Cancer Cell       Date:  2018-11-12       Impact factor: 31.743

Review 9.  Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.

Authors:  Bing Li; John O Mascarenhas; Raajit K Rampal
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 10.  Deregulated Polycomb functions in myeloproliferative neoplasms.

Authors:  Goro Sashida; Motohiko Oshima; Atsushi Iwama
Journal:  Int J Hematol       Date:  2019-01-31       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.